Novavax Inc today announced that it has revised its deal with world's largest vaccine manufacturing company Serum Institute of India (SII) in order to produce 2 billion doses of Covid-19 vaccines. In August, Novavax signed a deal with Pune-based Serum Institute to produce a minimum of one billion doses of its vaccine candidate for low-and middle-income countries and India. However, as a part of the expanded agreement, Serum Institute will also manufacture the antigen component of NVX‑CoV2373, Novavax’ COVID‑19 vaccine candidate. “Today’s agreement with Serum Institute enhances Novavax’ commitment to equitable global delivery of our COVID-19 vaccine. It is estimated that about 65% of the children in the world receive at least one vaccine manufactured by Serum Institute.

Source: Mint September 15, 2020 11:26 UTC